Dr. John Cush RheumNow
4 years 6 months ago
Changing to a new biologic or sticking with the old one - a PsA patient chooses
QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/VJ5tuLN6ae https://t.co/OrxVBwNUsx
Dr. John Cush RheumNow
4 years 6 months ago
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
https://t.co/PcQC6sQWyu https://t.co/Dqsq6BneM9
Dr. John Cush RheumNow
4 years 6 months ago
Failed Osteoarthritis Pulse Ultrasound Study
https://t.co/6JpiVBOfuV https://t.co/3F4iRVZjUs
The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of convalescent patients.
A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.
Dr. John Cush RheumNow
4 years 6 months ago
Single center study of individualized anakinra use in 47 autoinflammatory pts (32kids; 43% MAS; 40% systemic JIA). Off-label use in 38%, higher doses in 21 kids (5-29mg/kg); & 5 given IV anakinra; such doses were well tolerated without major AE. https://t.co/wQgw3YAPKX https://t.co/zL3HfdX4Ns
Dr. John Cush RheumNow
4 years 6 months ago
Juvenile CADM: JAMA Case - 6 yoF with 4 yrs of rash on hands, feet, elbows, knees. No Resp to topicals. ROS rare cough & SOB; no weakness. Gottrons over hands, knee. Bx +, ANA+ 1:320, nl enzymes, MSA- See how she was Rx https://t.co/l26Y666JKZ https://t.co/XlzWNKILJU
Dr. John Cush RheumNow
4 years 6 months ago
Good review of Diagnosis and Treatment of Pulmonary Sarcoidosis in JAMA.
- Lung progression (in only 10%) assoc w/ 12-18% 5yr mortality
- Sx Sarcoid w/ Lung: start Pred 20 to 40 mg/d for 2 -6 wks
- Steroid sparing w/ MTX, AZA or TNFi https://t.co/ylF8KR47gc https://t.co/VUvjYYC8gG
Dr. John Cush RheumNow
4 years 6 months ago
Shared Decision Making in PsA
Changing to a new biologic or sticking with the old one - a PsA patient chooses
QD Clinic is sponsored by https://t.co/4UQlqwujiR
(March 19 & 20, 2022 in Las Colinas, Texas)
https://t.co/Hc7ctWtj7A https://t.co/BAApPkxefc
Dr. John Cush RheumNow
4 years 6 months ago
We are excited to announce that Dr. Philip Mease will be joining us at RheumNow Live, leading a presentation and discussion on Axial Psoriatic Arthritis & Fatigue and Central Sensitization.
Join the discussion on March 19-20, on site or virtually!
https://t.co/AIteIEHY9E https://t.co/ybXhIelSgM
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality. BAR joins dexamethasone and tocilizumab as anti-inflammatory treatments capable of reducing the risk of death in COVID-19.
Dr. John Cush RheumNow
4 years 6 months ago
Gout is common but disproportionately affects certain groups (e.g., the elderly, Pacific Islander, Blacks). Ethnic links to gout were also recently shown to be linked to modifiable behavioral factors that may prove useful in managing gout patients.
https://t.co/uvIuw3zFnq https://t.co/EZomBGQIyt
A promising therapy aimed at halting and even reversing the pathology underlying osteoarthritis (OA) of the knee failed to show any benefit in a randomized trial.
Neither clinical nor radiographic outcomes differed between patients who received pulsed low-intensity ultrasound (PLIUS) for 48 weeks and a sham-treated control group, according to Allen D. Sawitzke, MD, of the University of Utah in Salt Lake City, and colleagues.
